Search

Your search keyword '"Giralt, S."' showing total 97 results

Search Constraints

Start Over You searched for: Author "Giralt, S." Remove constraint Author: "Giralt, S." Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
97 results on '"Giralt, S."'

Search Results

7. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis

10. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

14. A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation

17. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study

19. The effects of the NAO on the ice phenology of Spanish alpine lakes

21. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts

27. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance

28. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center

30. Cancer-testis antigen expression and immunogenicity in AL amyloidosis

31. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation

33. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis

34. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

39. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

44. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population

45. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research

46. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome

47. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

49. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies

Catalog

Books, media, physical & digital resources